Wedbush Boosts Shattuck Labs (NASDAQ:STTK) Price Target to $8.00

Shattuck Labs (NASDAQ:STTK) had its price target increased by research analysts at Wedbush from $4.00 to $8.00 in a report issued on Friday,Benzinga reports. The firm presently has an “outperform” rating on the stock. Wedbush’s price objective would suggest a potential upside of 33.56% from the stock’s previous close.

Other equities analysts also recently issued reports about the stock. Citigroup lifted their target price on shares of Shattuck Labs from $2.00 to $4.00 and gave the stock a “neutral” rating in a research note on Tuesday, January 6th. Piper Sandler started coverage on shares of Shattuck Labs in a report on Wednesday, January 28th. They set an “overweight” rating and a $15.00 price target for the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Shattuck Labs in a research report on Thursday, January 22nd. Finally, HC Wainwright upgraded Shattuck Labs from a “neutral” rating to a “buy” rating and set a $6.00 price objective on the stock in a report on Monday, December 1st. Six equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Shattuck Labs currently has an average rating of “Moderate Buy” and an average price target of $10.00.

Shattuck Labs Stock Up 17.5%

Shares of STTK opened at $5.99 on Friday. Shattuck Labs has a 52-week low of $0.69 and a 52-week high of $6.00. The stock has a fifty day simple moving average of $4.17 and a two-hundred day simple moving average of $2.84. The company has a market capitalization of $379.05 million, a PE ratio of -7.78 and a beta of 1.55.

Shattuck Labs (NASDAQ:STTK) last announced its quarterly earnings results on Thursday, March 5th. The company reported ($0.12) earnings per share for the quarter, meeting the consensus estimate of ($0.12). The firm had revenue of ($1.00) million for the quarter, compared to analyst estimates of $0.17 million. As a group, equities analysts anticipate that Shattuck Labs will post -1.48 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Shattuck Labs

A number of institutional investors have recently made changes to their positions in the stock. AQR Capital Management LLC raised its stake in shares of Shattuck Labs by 265.4% in the 1st quarter. AQR Capital Management LLC now owns 43,169 shares of the company’s stock valued at $41,000 after acquiring an additional 31,355 shares during the period. Jacobs Levy Equity Management Inc. purchased a new position in shares of Shattuck Labs during the 1st quarter worth approximately $81,000. Acadian Asset Management LLC increased its holdings in Shattuck Labs by 27.6% in the 1st quarter. Acadian Asset Management LLC now owns 257,345 shares of the company’s stock valued at $243,000 after purchasing an additional 55,687 shares during the last quarter. Y Intercept Hong Kong Ltd purchased a new stake in Shattuck Labs in the second quarter valued at approximately $98,000. Finally, Qube Research & Technologies Ltd purchased a new stake in Shattuck Labs in the second quarter valued at approximately $44,000. 58.74% of the stock is currently owned by institutional investors and hedge funds.

More Shattuck Labs News

Here are the key news stories impacting Shattuck Labs this week:

• Positive Sentiment: Needham & Company initiated coverage with a “Buy” and a $25.00 price target, implying a very large upside potential vs. the current price; this is a major bullish catalyst for investor interest. Needham coverage
• Positive Sentiment: Wedbush raised its price target from $4.00 to $8.00 and kept an “Outperform” rating — a supportive signal from another sell‑side shop that likely contributed to the intraday move. Wedbush note
• Neutral Sentiment: HC Wainwright reiterated a “Buy” rating and a $6.00 price target while publishing detailed quarterly and multi‑year EPS forecasts for 2026–2028; the reiteration provides some analyst-level support but with a much lower target than Needham. HC Wainwright coverage
• Negative Sentiment: HC Wainwright lowered its EPS forecasts across FY‑2026 to FY‑2028 (FY‑2026: now ($0.83) from ($0.71); FY‑2027: now ($0.88) from ($0.76); FY‑2028: now ($1.04) from ($0.90)) and issued quarterly EPS projections for 2026 (Q1 ($0.18), Q2 ($0.19), Q3 ($0.22), Q4 ($0.24)). Those cuts signal weaker near‑term profitability expectations and are a negative for fundamentals despite the maintained Buy rating.

About Shattuck Labs

Shattuck Labs, Inc (NASDAQ: STTK) is a clinical‐stage biotechnology company headquartered in Cambridge, Massachusetts. The company is focused on developing immunotherapeutic vaccines to prevent and treat substance use disorders, with an initial emphasis on opioids. Shattuck Labs employs a proprietary hapten‐carrier conjugate technology designed to generate high‐affinity drug‐specific antibodies that sequester target molecules in the bloodstream and reduce their passage across the blood‐brain barrier.

The company’s lead program targets fentanyl, a synthetic opioid responsible for a significant proportion of overdose fatalities.